Background {#Sec1}
==========

Subfebrile temperature or fever is common in patients with acute stroke. Body temperatures over 37.5°C have been reported in up to a quarter of patients within the first 6 h \[[@CR19]\], and in about a third at 24 h after stroke onset \[[@CR7]\]. This elevation of body temperature may be a direct consequence of brain damage inflicted by stroke, or a result of an associated infection \[[@CR8]\].

Increased body temperature markedly exacerbates neuronal injury in experimental models of cerebral ischemia \[[@CR13]\]. An association between increased body temperature and poor outcome has also been shown in patients with acute stroke \[[@CR3], [@CR4], [@CR7], [@CR12], [@CR14]--[@CR17], [@CR19]--[@CR21], [@CR23]\]. However, the temporal profile of this relation is not well established. Several prospective studies found that high body temperature on admission was associated with poor outcome \[[@CR3], [@CR7], [@CR16], [@CR19], [@CR20], [@CR23]\]. Others found that an increased body temperature within the first days after stroke onset was a prognostic factor for unfavorable outcome \[[@CR4], [@CR12], [@CR20], [@CR21]\].

The aim of our study was to assess the relationship between body temperature within the first 12 h after symptom onset, and the change in body temperature from admission to 24 h thereafter on the one hand, and functional outcome and death on the other, in a large sample of stroke patients.

Methods {#Sec2}
=======

All patients participated in the Paracetamol (Acetaminophen) In Stroke (PAIS) trial. The PAIS trial was a multicenter, randomized, placebo-controlled clinical trial of high-dose acetaminophen in patients with acute stroke \[[@CR10]\]. In short, patients with ischemic stroke or intracerebral hemorrhage with no history of liver disease or significant pre-stroke impairment (grade on the modified Rankin Scale (mRS) ≥2) \[[@CR22]\] were included within 12 h of symptom onset and treated with high-dose acetaminophen (6 g daily) or placebo for the next 3 days.

Clinical characteristics {#Sec3}
========================

Baseline clinical information included stroke severity assessed by means of the NIH Stroke Scale (NIHSS \[[@CR6]\]), ischemic stroke subtype according to the TOAST classification \[[@CR2]\], and cardiovascular risk factors. In addition, any infection that led to prolonged hospital stay or was life threatening was recorded. The diagnosis of infection was left with the treating physician.

Body temperature {#Sec4}
================

Body temperature was measured with a tympanic or rectal thermometer within 12 h from stroke onset and 24 h later. In each patient, a similar method of thermometry was used at these two points in time.

Outcome measures {#Sec5}
================

Poor outcome was defined as a grade of more than two on the mRS at 3 months from stroke onset. Scores on the mRS range from 0 (no symptoms at all) to 5 (severe disability); for statistical purposes, death has a score of six.

A secondary outcome measure was death at 3 months. Outcome assessment was blinded for body temperature.

Statistical analysis {#Sec6}
====================

Statistical analyses were performed with Stata/SE 9.2 for Windows (Statacorp, College Station, TX, USA). The relation between body temperature on admission and the change in body temperature from admission to 24 h thereafter (adjusted for admission body temperature) on the one hand and poor outcome or death on the other, was expressed as an odds ratio per 1.0°C increase in body temperature with a corresponding 95% confidence interval (CI), as estimated with logistic regression.

Adjustments were made with a multiple logistic regression model that included the following factors: age, sex, baseline NIHSS score, stroke type (ischemic stroke vs. intracerebral hemorrhage), ischemic stroke subtype (lacunar vs. non-lacunar infarction), treatment with rtPA, and the occurrence of infections. We performed additional analyses to account for the potential confounding effect of antipyretic treatment by stratifying for treatment with acetaminophen, which was the experimental drug treatment in the PAIS trial.

Furthermore, we assessed the relation between several clinical variables including stroke type, ischemic stroke subtype, and stroke severity (expressed in quartiles of the baseline NIHSS score) and the change in body temperature from baseline to 24 h thereafter (adjusted for admission body temperature) with multiple linear regression.

Results {#Sec7}
=======

Included into the PAIS trial were 1,400 patients with a clinical diagnosis of ischemic stroke or intracerebral hemorrhage. Of these patients, 68 were excluded from the present study either because the final diagnosis was not a stroke (*n* = 3) or because body temperature at 24 h was not recorded (*n* = 65).

In the remaining 1,332 patients, mean age was 70 years (SD 13), 56% of the patients were male, and 88% had an ischemic stroke (Table [1](#Tab1){ref-type="table"}). The infarction was of the lacunar type in 193 patients (17%). The median score on the NIHSS scale was 6 (range 0--30). Median time from stroke onset to measurement of the admission body temperature was 6 h (IQR 240--540). A total of 660 patients (50%) was treated with acetaminophen.Table 1Baseline clinical characteristics of the patients (*n* = 1,332)Demographics Mean (SD) age (years)70 (13) Sex (male)749 (56%)Cardiovascular risk factors Hypertension652 (49%) Atrial fibrillation198 (15%) Diabetes mellitus195 (15%) Current cigarette smoking390 (29%) Hypercholesterolemia332 (25%)Medical history Stroke267 (20%) Myocardial infarction155 (12%) Peripheral vascular disease128 (10%)Stroke type Ischemic stroke1,169 (88%)Ischemic stroke subtype^a^ Large vessel disease (≥50% stenosis)146 (12%) Cardiac source of embolism216 (18%) Small vessel occlusion193 (17%) Other determined etiology90 (8%) Undetermined477 (41%) Missing information47 (4%)Stroke severity Median (range) NIHSS score^b^6 (0--30)Physical examination Mean (SD) body temperature (°C)36.9 (0.6) Median (IQR) time from stroke onset to measurement of baseline body temperature (min)360 (240--540)Treatment Acetaminophen660 (50%) Intravenous alteplase281 (21%)^a^Based on the trial of ORG 10172 in Acute Stroke Therapy (TOAST) criteria^b^Scores on the National Institutes of Health Stroke Scale (NIHSS)

The mean body temperature was 36.9°C (SD 0.6) on admission, and 37.1°C (SD 0.7) 24 h later. Body temperature over 37.5°C was observed in 160 patients (12%) on admission and in 298 (22%) 24 h later. The increase in body temperature from baseline to 24 h thereafter was larger in patients with body temperatures of 37.0°C or less than in those with body temperatures over 37.0°C (Fig. [1](#Fig1){ref-type="fig"}).Fig. 1The change in body temperature in the first 24 h from admission to 24 h thereafter (ºC) as a function of body temperature on admission (ºC)

After 24 h, 96 of 660 patients (15%) treated with acetaminophen and 202 of 672 patients (30%) on placebo had a body temperature over 37.5°C (difference 15%; 95% CI 11--19%). Treatment with acetaminophen was associated with a 0.26°C (95% CI, 0.18--0.31) reduction in mean body temperature measured 24 h after admission.

Four of the 160 patients (3%) with baseline body temperatures over 37.5°C and 24 of 298 patients (8%) with body temperatures over 37.5°C 24 h later developed an infection during hospitalization.

The proportion of patients with admission body temperatures over 37.5°C was similar in patients with ischemic stroke \[145/1,169 (12%) \[and in those with intracerebral hemorrhage \[16/163 (10%)\] and also in patients with non-lacunar infarction \[136/1,139 (10%)\] and lacunar infarction \[24/193 (12%)\]. However, the increase in body temperature from admission to 24 h thereafter was 0.24°C larger (95% CI, 0.14--0.33) in patients with non-lacunar infarction than in those with lacunar infarction and also 0.33°C (95% CI, 0.23--0.44) larger in patients with intracerebral hemorrhage than in patients with ischemic stroke.

We did not observe a proportional increase in the association between stroke severity and body temperature on admission. However, in the highest quartile of the NIHSS score (NIHSS score ≥13), baseline body temperature was 0.20°C (95% CI, 0.12--0.27) lower than body temperature in the lower quartiles of the NIHSS score (NIHSS \<13) (Fig. [2](#Fig2){ref-type="fig"}). Body temperature 24 h later was associated with baseline stroke severity. For every quartile of the NIHSS score, body temperature at 24 h rose on average with 0.16°C (95% CI, 0.13--0.19) (Fig. [2](#Fig2){ref-type="fig"}).Fig. 2Stroke severity (*quartiles*) and body temperature within 12 h from stroke onset, (*grey bars*) and 24 h later (*black bars*)

Body temperature on admission was not related to poor outcome or death (Table [2](#Tab2){ref-type="table"}). An increased body temperature in the first 24 h after admission, however, was associated with poor outcome or death at 3 months (Table [2](#Tab2){ref-type="table"}). Adjustment for potential confounders slightly attenuated this association (Table [2](#Tab2){ref-type="table"}). An additional stratified analysis to account for the potentially modifying effect of treatment with acetaminophen did not affect the association (Table [2](#Tab2){ref-type="table"}).Table 2Association of body temperature with poor outcome or death at 3 monthsPoor outcomeOverallOverallaOR (95% CI)^ab^OR (95% CI)^a^aOR (95% CI)^ab^AcetaminophenPlaceboWithin 12 h from stroke onsetmRS \>2 (*n* = 663)0.82 (0.68--0.98)1.06 (0.85--1.32)0.91 (0.66--1.26)1.19 (0.87--1.64)Death (*n* = 218)0.87 (0.68--1.12)1.23 (0.95--1.60)1.10 (0.74--1.63)1.37 (0.96--1.96)Change from admission to 24 h^c^mRS \>2 (*n* = 663)1.98 (1.65--2.39)1.30 (1.05--1.63)1.22 (0.86--1.73)1.35 (1.00--1.83)Death (*n* = 218)2.36 (1.86--2.99)1.51 (1.15--1.98)1.51 (0.97--2.36)1.61 (1.11--2.31)^a^Per 1.0° Celsius increase of body temperature^b^Adjusted for age, sex, NIHSS score, stroke type, ischemic stroke subtype, treatment with rtPA, and occurrence of infections^c^Adjusted for body temperature on admission

After exclusion of patients who developed an infection during the first 2 weeks after stroke onset, the adjusted odds ratio for poor outcome was 1.30 (95% CI 1.04--1.63), and for death 1.50 (95% CI 1.12--2.00).

Figure [3](#Fig3){ref-type="fig"} illustrates the strength of the association between the change in body temperature from admission to 24 h thereafter and poor outcome. The absolute difference in the risk of poor outcome between patients in the lowest and patients in the highest body temperature category is more than 20%.Fig. 3Probability of poor outcome (mRS \>2) at 3 months in relation to change in body temperature from baseline to 24 h thereafter (*sixtiles*) (ºC)

Discussion {#Sec8}
==========

Our results do not confirm the previously reported association between high body temperature on admission and unfavorable outcome in patients with acute stroke. However, patients with increased body temperatures in the first 24 h after admission did have an increased risk of poor functional outcome or death at 3 months.

Before these results can be interpreted, some methodological issues have to be discussed. First, one of the strengths of our study is its large sample size. Other strengths include robust outcome measures and detailed information on confounders. Second, PAIS was a randomized double-blind placebo-controlled trial that addressed the question of whether temperature reduction by acetaminophen would improve outcome in patients with acute stroke \[[@CR10]\]. Half of the study population was treated with acetaminophen in a daily dose of 6 g for three consecutive days. As a result, body temperature at 24 h after admission was lowered and fewer patients may have experienced a poor outcome, although the overall effect of acetaminophen on outcome was not statistically significant. We did separate regression analyses in the patients treated with acetaminophen and those allocated to placebo. The estimates of the association between the change in body temperature from admission to 24 h thereafter and outcome were similar in the two groups, suggesting that the study population could be analyzed as one group.

A third issue is that we only recorded body temperature at two points in time, i.e., within 12 h from symptom onset and 24 h later and did not repeat measurements of body temperature. As a consequence, it might be more difficult to compare our results with the results of previous studies.

Finally, relatively few patients with very severe stroke were included, possibly because we did not specify a lower NIHSS score limit in the eligibility criteria of the PAIS trial. However, our results showed that patients with more severe strokes had higher body temperatures at 24 h after admission, and thereby underrepresentation of patients with severe strokes potentially weakens rather than exaggerates the observed relation between body temperature at 24 h after admission and poor outcome.

Previous studies have found that increased body temperature within 6 h up to at least 24 h after stroke onset is an independent prognostic factor for poor outcome \[[@CR3], [@CR4], [@CR7], [@CR12], [@CR14]--[@CR17], [@CR19]--[@CR21], [@CR23]\]. However, the temporal profile of this association is still under debate. Several studies showed that high body temperature on admission was associated with poor outcome \[[@CR3], [@CR7], [@CR15]\]. In three of these, no adjustments were made for baseline stroke severity assessed with validated stroke scales \[[@CR2], [@CR5], [@CR8]\]. In a prospective study of 390 patients with either ischemic stroke or intracerebral hemorrhage admitted within 6 h of symptom onset, the odds of poor outcome doubled for every degree of Celsius increase in baseline body temperature \[[@CR19]\]. We found that patients with severe stroke had relatively low body temperatures at baseline, possibly because of a faster loss of body temperature before hospital admission as a result of less muscle activity. This finding might explain in part that body temperature on admission was not associated with clinical outcome.

A prospective study of 725 patients admitted within 6 h of symptom onset found a relation between increased body temperature at 10--12 h after stroke onset and poor outcome, but no relationship between body temperature on admission and poor outcome was found \[[@CR4]\]. Although these results seem contradictory to our findings, our results indeed suggest that increased body temperature in the first 24 h after admission rather than body temperature on admission is an important prognostic factor for clinical outcome after stroke. In line with our results, a recent study of 5,305 patients with ischemic stroke from the Virtual International Stroke Trials Archive found that an increase in body temperature from baseline rather than high body temperature on admission was a strong risk factor for poor outcome \[[@CR20]\]. As the data came from different randomized trials, body temperature was dichotomized at 37.2°C and follow-up temperatures were only available for a third of the patients.

Two others showed that increased body temperature relative to baseline in the first 24--72 h after stroke onset was associated with unfavorable outcome \[[@CR12], [@CR21]\]. These studies included only patients with intracerebral hemorrhage \[[@CR21]\] or patients with ischemic stroke treated with intravenous thrombolysis \[[@CR12]\].

In a recent prospective study with 250 patients with ischemic stroke, the association between body temperature and unfavorable outcome was dependent on treatment with alteplase \[[@CR17]\]. High body temperature in the first 6 h from symptom onset was associated with favorable outcome in patients treated with alteplase, and low body temperature was associated with favorable prognosis in those not treated with alteplase. In the present study, we could not confirm that the association between body temperature and outcome is dependent on treatment with rtPA.

Increased body temperature may be attributed to a systemic inflammatory response following ischemic stroke or to accompanying infections. In addition, it has been suggested that increased body temperature indicates hypothalamic damage following stroke \[[@CR18]\]. The mechanisms of the association between an early rise in body temperature and poor outcome remain speculative. Secondary infections are common in the first week of stroke and are associated with poor outcome, but they usually occur more than 12 h after stroke onset \[[@CR11]\]. In our study, only 8% of patients with body temperatures over 37.5°C developed an infection during hospitalization. Besides, the relationship between body temperature at 24 h after admission and poor outcome was independent of the occurrence of infections. Furthermore, exclusion of patients developing an early infection during hospitalization did not substantially affect the relation between body temperature and poor functional outcome or death. Therefore, infections cannot account for the observed relation between temperature and outcome.

The change in body temperature from admission was associated with baseline stroke severity. One may argue that increased body temperature does not accelerate the ischemic cascade, but merely reflects extensive cerebral damage and, thereby, of poor outcome. However, the relation between increased body temperature and poor outcome was independent of baseline stroke severity.

Our results provide a rationale for the hypothesis that prevention of an early rise in body temperature could reduce death and improve functional outcome. Guidelines for the treatment of patients with acute ischemic stroke \[[@CR1]\] or intracerebral hemorrhage \[[@CR5]\] recommend the administration of antipyretic medication in case of fever or a temperature above 37.5°C. This might be too late, as the rise in body temperature has already occurred, and the time period in which the brain lesion is most vulnerable has subsided. On the other hand, there is still no convincing evidence from randomized trials that strategies to prevent or treat elevated body temperature reduce case fatality and improve functional outcome after stroke \[[@CR9], [@CR10]\].
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Appendix: Participating centers with names of investigators {#Sec9}
===========================================================

Meander MC Amersfoort (HMA van Gemert), Erasmus MC Rotterdam (DWJ Dippel), UMC Utrecht (HB van der Worp), Sint Fransicus Gasthuis Rotterdam (FH Vermeij), Slotervaart Ziekenhuis Amsterdam (VIH Kwa), Gelre ziekenhuizen Apeldoorn (HP Bienfait), TweeSteden ziekenhuis Tilburg (BPW Jansen), Sint Elisabeth Ziekenhuis Tilburg (PLM de Kort), Westfriesgasthuis Hoorn (TC van der Ree), Maasstad ziekenhuis Rotterdam (R Saxena), Ziekenhuis Bethesda Hoogeveen (PG Oomes), Dirksland Ziekenhuis Dirksland (UW Huisman), Sint Lucas Andreas Ziekenhuis Amsterdam (EJ Wouda), Martini Ziekenhuis Groningen (C Bouwsma), Catharina Ziekenhuis Eindhoven (K Keizer) Albert Schweitzer ziekenhuis Dordrecht (RP Kleyweg/H Kerkhoff), Amphia Ziekenhuis Breda (HBC Verbiest/SLM Bakker), Rijnland Ziekenhuis Leiderdorp (ELLM De Schryver), Diakonessenhuis Utrecht (RCJM Donders), Slingeland Ziekenhuis Doetinchem (RA van der Kruijk), IJsselland Ziekenhuis Capelle aan den Ijssel (J Heerema), Jeroen Bosch Ziekenhuis Den Bosch (RAJAM Bernsen), Ziekenhuis Hilversum Hilversum (D Herderschêe), Diaconessenhuis Meppel (EJW Keuter), Vlietlandziekenhuis Schiedam (WC Baart), Spaarne Ziekenhuis Hoofddorp (RJ Meijer), Beatrixziekenhuis Gorinchem (RB Alting van Geusau), Streekziekenhuis Koningin Beatrix Winterswijk (JP de Ruiter), Wilhelmina Ziekenhuis Assen (JN Wessel/AE Bollen).
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